Rajiv Kumar

Employment

• Mercy Cancer Care Medical Oncologist
  2021 - Present
• St George's Cancer Care Centre Medical Oncologist
  2020 - Present
• New Zealand Clinical Research Principal Investigator
  2020 - 2021
• Canterbury District Health Board Medical Oncologist - Maternity Cover | Fixed Term Contract
  2019 - 2020
• Royal Marsden NHS Foundation Trust Lung Cancer and Breast Cancer
  2019 - 2019
• Croydon University Hospital Medical Oncologist
  2019 - 2019
• Epsom and St Helier University Hospitals NHS Trust Medical Oncologist
  2018 - 2019
• Institute of Cancer Research Higher Research Degree Candidate
  2015 - 2018
• Royal Marsden NHS Foundation Trust Clinical Research Fellow
  2014 - 2018
• Royal Marsden NHS Foundation Trust Clinical Research Fellow
  2013 - 2014
• Flinders Medical Centre Clinical Research Fellow
  2012 - 2013
• Te Whatu Ora Advanced Trainee in Medical Oncology
  2008 - 2012

Education

• University of Otago BMedSci (Distinction) - Bachelor of Medical Science (Distinction). Thesis: PAX2 gene in early metanephric development
  2021 - 2021
• University of London MD (Res) Doctor of Medicine - Research. Thesis: A phase 1 dose escalation study of pembrolizumab combined with palliative thoracic radiotherapy
  2015 - 2018
• Royal Australasian College of Physicians FRACP - Fellow of the Royal Australasian College of Physicians
  2012 - Present
• University of Otago MB ChB - Bachelor of Medicine and Bachelor of Surgery
  1998 - 2004

Projects & Funding

Projects & funding information is unavailable.

Publications (55)

• Towards implementation of precision medicine biomarkers in early detection and prognostication of prostate cancer
  Cancer and Metastasis Reviews 2026 DOI: 10.1007/s10555-026-10357-8
  +Save
• Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non–Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study
  JMIR Research Protocols 2026 DOI: 10.2196/105338
  +Save
• Cell-free DNA methylation in the clinical management of lung cancer
  Trends in Molecular Medicine 2024 DOI: 10.1016/j.molmed.2024.03.007
  +Save
• Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
  New England Journal of Medicine 2023 DOI: 10.1056/nejmoa2303810
  +Save
• A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
  Cancer Immunology, Immunotherapy 2023 DOI: 10.1007/s00262-023-03400-y
  +Save
• Abstract OT2-11-01: A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: interim results
  Cancer Research 2023 DOI: 10.1158/1538-7445.sabcs22-ot2-11-01
  +Save
• The Predictive Value of the G8 Questionnaire in Older Patients with Lung Cancer or Mesothelioma before Systemic Treatment
  Clinical Oncology 2023 DOI: 10.1016/j.clon.2022.10.020
  +Save
• 126P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer (NSCLC)
  Immuno-Oncology and Technology 2022 DOI: 10.1016/j.iotech.2022.100238
  +Save
• EP08.01-073 AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
  Journal of Thoracic Oncology 2022 DOI: 10.1016/j.jtho.2022.07.645
  +Save
• Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperable Pancreatic Adenocarcinoma.
  Pancreas 2022 DOI: 10.1097/mpa.0000000000002065
  +Save